Polymorphisms in ERCC1 and XPF gene and response to chemotherapy and overall survival of non-small cell lung cancer

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 3, 2015, Pages 3132-3137

  Shi, Zong Hua ^a   Shi, Guang Yong ^a   Liu, Lin Gang ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

Clinical outcome; ERCC1; Non small cell lung cancer; Polymorphism; XPF

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; XERODERMA PIGMENTOSUM GROUP F PROTEIN;

ADULT; AGED; DRUG RESISTANCE; FEMALE; GENETICS; GENOTYPE; HUMAN; KAPLAN MEIER METHOD; LUNG TUMOR; MALE; MIDDLE AGED; MORTALITY; NON SMALL CELL LUNG CANCER; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; FEMALE; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES;

EID: 84933033921     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. International Agency for Research on Cancer. Lung Cancer. Estimated Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed in 2014-1-1.
2. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2: 985.
3. Alberts DS, Garcia D, Mason-Liddil N. Cisplatin in advanced cancer of the cervix: an update. Semin Oncol 1991; 18: 11-24.
4. Zhou F, Yu Z, Jiang T, Lv H, Yao R, Liang J. Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. Swiss Med Wkly 2011; 141: w13275.
5. Evans WE and Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487-491.
6. Tuteja N, Tuteja R. Unraveling DNA repair in human: molecular mechanisms and consequences of repair defect. Crit Rev Biochem Mol Biol 2001; 36: 261-90.
7. Wang AT, Sengerová B, Cattell E, Inagawa T, Hartley JM, Kiakos K, Burgess-Brown NA, Swift LP, Enzlin JH, Schofield CJ, Gileadi O, Hartley JA, McHugh PJ. Human SNM1A and XPF-ERCC1 collaborate to initiate DNA interstrand cross-link repair. Genes Dev 2011; 25: 1859-70.
8. Chen ZH, Wang L, Luo LP. Association of DNA repair gene polymorphisms with response to chemotherapy and prognosis of gastric cancer. Genet Mol Res 2014; 13: 7484-91.
9. Huang SJ, Wang YF, Jin ZY, Sun JY, Guo ZL. Role of ERCC1 variants in response to chemotherapy and clinical outcome of advanced non-small cell lung cancer. Tumour Biol 2014; 35: 4023-9.
10. Bauman JE, Austin MC, Schmidt R, Kurland BF, Vaezi A, Hayes DN, Mendez E, Parvathaneni U, Chai X, Sampath S, Martins RG. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial. Br J Cancer 2013; 109: 2096-105.
11. McNeil EM, Melton DW. DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy. Nucleic Acids Res 2012; 40: 9990-10004.
12. Fleming ND, Agadjanian H, Nassanian H, Miller CW, Orsulic S, Karlan BY, Walsh CS. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer. Cancer 2012; 118: 689-97.
13. Zhao X, Zhang Z, Yuan Y, Yuan X. Polymorphisms in ERCC1 gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients. Tumour Biol 2014; 35: 8335-41.
14. Xie F, Sun Q, Wu S, Xie X, Liu Z. Nucleotide excision repair gene ERCC1 19007T>C polymorphism contributes to lung cancer susceptibility: a meta-analysis. Genet Test Mol Biomarkers 2014; 18: 591-5.
15. Lv H, Han T, Shi X, Yao Y, Yao Y, Qiu W, Yue L, Liang J. Genetic polymorphism of GSTP1 and ERCC1 correlated with response to platinum-based chemotherapy in non-small cell lung cancer. Med Oncol 2014; 31: 86.
16. Mlak R, Krawczyk P, Ramlau R, Kalinka-Warzocha E, Wasylecka-Morawiec M, Wojas-Krawczyk K, Kucharczyk T, Homa I, Koziol P, Ciesielka M, Chudziak D, Milanowski J. Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients. Oncol Rep 2013; 30: 2385-98.
17. Rumiato E, Cavallin F, Boldrin E, Cagol M, Alfieri R, Basso D, Castoro C, Ancona E, Amadori A, Ruol A, Saggioro D. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy. Pharmacogenet Genomics 2013; 23: 597-604.
18. Chen C, Wang F, Wang Z, Li C, Luo H, Liang Y, An X, Shao J, Li Y. Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol 2013; 72: 315-22.
19. Hao T, Feng W, Zhang J, Sun YJ, Wang G. Association of four ERCC1 and ERCC2 SNPs with survival of bone tumour patients. Asian Pac J Cancer Prev 2012; 13: 3821-4.
20. Deloia JA, Bhagwat NR, Darcy KM, Strange M, Tian C, Nuttall K, Krivak TC, Niedernhofer LJ. Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum. Gynecol Oncol 2012; 126: 448-54.
21. Sullivan I, Salazar J, Majem M, Pallarés C, Del Río E, Páez D, Baiget M, Barnadas A. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Lett 2014; 353: 160-6.
22. Xu TP, Shen H, Liu LX, Shu YQ. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports. Gene 2013; 526: 265-74.
23. Kornguth DG, Garden AS, Zheng Y, Dahlstrom KR, Wei Q, Sturgis EM. Gastrostomy in oropharyngeal cancer patients with ERCC4 (XPF) germline variants. Int J Radiat Oncol Biol Phys 2005; 62: 665-71.
24. Fareed KR, Al-Attar A, Soomro IN, Kaye PV, Patel J, Lobo DN, Parsons SL, Madhusudan S. Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Br J Cancer 2010; 102: 1600-7.